What Masivet Treats: Main Uses and Benefits

Masivet is generally applied in the field of targeted veterinary oncology and is relevant in addressing conditions marked by increased physiological stress. The medicine is commonly used to help with management of non-resectable mast cell tumors (MCTs) in dogs, primarily those classified as Patnaik Grade 2 or Grade 3 that are confirmed to possess the mutated c-kit receptor. This application is relevant in clinical settings where local control via surgery is not feasible, making systemic management appropriate.

The medicine plays a role in managing clusters of systemic symptoms linked to these conditions, such as chronic vomiting, diarrhea, and anorexia. In situations involving heightened systemic burden, this intervention provides support that helps ease the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods. This therapy is relevant for easing distress and assists with maintaining functional stability during difficult episodes.

---

Quick Fact: Support for Symptoms Related to Systemic Imbalance
Symptoms Addressed	Systemic distress, gastrointestinal upset, and chronic appetite loss linked to inflammatory or irritative states.
Common Scenario	Used when tumors are non-resectable or advanced, requiring systemic control.
Benefit Focus	Contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. European Medicines Agency product information

Eligibility for Masivet (Masitinib)

The use of Masivet is strictly limited to dogs that meet specific clinical, pathological, and developmental criteria as defined in official regulatory labeling (EMA).

Status	Specific Criteria
Allowed Use	Dogs with non-resectable mast cell tumours (Grade 2 or 3) that are confirmed to possess the mutated c-kit tyrosine kinase receptor. Surgery is the required first-line treatment for resectable tumours.
Contraindicated	Dogs with known hypersensitivity to masitinib or excipients.

Absolute Contraindications (Must Not Use)

Treatment is explicitly prohibited for dogs if they present with any of the following conditions, defined by specific laboratory thresholds:

• Age/Weight/Reproduction: Dogs less than 6 months of age or less than 4 kg body weight. Use is also forbidden in pregnant or lactating bitches, and treated dogs must not be used for breeding.
• Liver Impairment: ALT or AST greater than 3 imes Upper Limit of Normal (ULN).
• Renal Impairment: Urinary Protein Creatinine (UPC) ratio greater than 2 or albumin less than 1 imes Lower Limit of Normal (LLN).
• Hematological Status: Anaemia (haemoglobin less than 10 g/dl) or neutropenia (absolute neutrophil count less than 2,000 /mm^3).

Interactions with other medicines and products

The official regulatory profile for Masivet (Masitinib mesylate) describes potential interaction patterns based on the drug's core pharmacological properties, rather than listing specific prohibited combinations.

---

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Officially Documented Statement
Metabolic Pathway	Co-administration with substances that are metabolised by CYP450 isoforms may result in a change to the plasma levels of either Masitinib or the co-administered drug.
Protein Binding	Concurrent use of other highly protein-bound substances may compete with Masitinib binding, a pattern documented as potentially causing adverse effects.

The statement regarding the CYP450 interaction is based on in vitro data, with regulatory documents noting that the specific corresponding in vivo information is not available for the target species.

---

Restrictions and Conditions

Interaction-Related Restriction	Regulatory Status
Formal Contraindications	None are explicitly listed in the regulatory documentation based on interaction risk alone.
Mandatory Timing Rules	No specific time separation rules for administration are mandated in the official prescribing information.

Additionally, regulatory documents note a population-specific consideration: the expected efficacy of Masivet might be reduced in dogs that have a documented history of prior treatment involving chemotherapy and/or radiotherapy. The official profile does not document specific interactions with food, alcohol, or herbal products.

How Masivet Works

Masivet's mechanism is defined by its role as a targeted Tyrosine Kinase Inhibitor (TKI), which works by selectively blocking key enzyme activity within target cells.

---

Dual Inhibition of Pro-Survival and Angiogenic Signaling

Masitinib directly inhibits the enzyme function of the c-Kit receptor and the Platelet-Derived Growth Factor Receptors (PDGFR- alpha/ beta). By binding to the ATP pocket of these kinases, Masitinib prevents the signal transduction necessary for cell survival and division. This targeted signaling arrest triggers apoptosis (programmed cell death) in cells dependent on c-Kit activity while simultaneously limiting the formation of new blood vessels (anti-angiogenesis), a process critical for maintaining the target tissue's vascularization.

---

Systemic Containment via Pathway Modulation

The drug's activity is not limited to a single target; it also modulates other intracellular kinases like Lyn and Fyn. This wider mechanistic domain suppresses the signals that regulate cellular motility and the capacity for tissue dissemination. This multi-target intervention—combining anti-proliferation, programmed cell death, anti-angiogenesis, and reduced motility—results in a coordinated physiological effect that limits the expansion and reduces the number of target cells. The mechanism is dependent on the target kinases being active; if cells develop compensatory survival pathways, the inhibitory action on proliferation may become constrained.

Instruction Map: How to use Masivet — Administration Guidelines

Administration Scope

Instruction	Detail
Route of administration	The medicine is for oral use only.
Dosing schedule	The recommended starting dose is 12.5 mg/kg of body weight, which falls within the dose range of 11–14 mg/kg.
Timing in relation to meals (if applicable)	Administration must always occur with food to maintain consistent use conditions.
Preparation requirements (if applicable)	The film-coated tablets must be administered as a whole and are not to be divided, broken, or crushed.
Age-group administration rules	Dosing is weight-based, and for patients weighing less than 15 kg, the tablet strength must be selected to ensure the dosage remains within the target range.
Missed-dose rules	If a tablet is regurgitated or vomited within 10 minutes of administration, a replacement dose is given. If the tablet is rejected after this time window, the dose should not be repeated.
Special procedural conditions	The treatment duration is response-dependent, continuing only as long as stable disease is maintained. Initial assessment of response is recommended within the first 4 to 6 weeks of therapy. Provisions exist for dose interruption or reduction as a usage pattern based on specific laboratory monitoring results.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Once daily (QD)
Use-context constraints	Weight-based calculation, with food, whole tablet administration, response-based duration.

---

Resulting Procedural Structure

Step sequence:

• Calculate the required dose based on the patient's body weight to achieve 12.5 mg/kg.
• Administer the whole, film-coated tablet orally, once daily, with food.
• Do not break, divide, or crush the tablet.

Connection to the overall use protocol: The Masivet protocol establishes a standardized, weight-dependent dosing regimen that is administered once per day alongside food. This structure ensures a consistent use pattern. The protocol mandates the administration of whole tablets and links the long-term duration of use directly to the observed patient response.

Research evidence / Overview of studies for Masivet

---

Overview of the Clinical Study Landscape

Research into Masitinib mesylate (Masivet) has primarily involved randomized, controlled clinical trials conducted during the regulatory process. These types of studies are often used as the primary basis for regulatory review because they compare the treatment protocol against a control group (such as a placebo) to observe differences in measured outcomes under strict conditions. These trials are relevant in evidence describing how symptoms are measured and how outcomes are tracked over defined time intervals. The findings describe patterns observed in the studies and contribute to the broader evidence landscape relied upon by regulatory bodies.

---

Research Evidence for Non-Resectable Mast Cell Tumors (MCTs)

The most significant research that forms the foundation for regulatory review is the pivotal Phase III trial, which was studied for its use in dogs with non-resectable cutaneous mast cell tumors (MCTs), specifically those classified as Grade 2 or Grade 3. Researchers examined specific outcomes related to tumor control, such as the Time-to-Tumor Progression (TTP), and monitored Overall Survival (OS). The research team reported measurements of tumor control outcomes for the Masitinib mesylate group and compared those measurements to the control group. The study results reflect the specific conditions under which they were conducted, which is why the research specifically focused on dogs with this particular, mutated tumor profile.

---

Duration of Effect and Long-Term Follow-up Data

Studies monitored the durability of outcomes by collecting long-term follow-up data on survival, often extending the observation period up to 12 months and 24 months after the core trial phase. This research examined whether the patterns observed in short-term studies continued over extended periods. While these long-term studies contribute to understanding symptom patterns, limited information for long-term outcomes is structured in the same rigorous double-blind manner as the initial trial. Certainty remains low regarding long-term effects because follow-up durations were limited in the most controlled part of the research.

Common questions about Masivet (FAQ)

---

Q: How quickly does Masivet start working, if it works?

Official product information indicates that an initial assessment of the tumour response is generally recommended during the first four to six weeks of therapy. This timeframe is when the veterinarian can determine if the treatment should be continued based on documented effects observed in studies.

---

Q: If I miss a dose of Masivet, what is the general guidance?

The regulatory guidance for this medicine directs users to consult with the prescribing veterinarian if a dose is missed. It is important to follow their specific instructions on how to handle the missed dose to maintain the intended treatment plan.

---

Q: What is the maximum duration Masivet has been studied for continuous use?

In the pivotal regulatory study, treatment was maintained in patients who showed a positive response or stable disease until the disease progressed. This resulted in follow-up information and analyses being reported for treatment periods up to 24 months. The duration of use is ultimately determined by the patient's individual response to therapy.

---

Q: Does Masivet treatment require frequent visits to the doctor?

Yes, official guidelines state that regular monitoring by a veterinarian is required throughout the treatment period. This involves an initial intensive monitoring schedule for some health parameters, followed by monthly reviews thereafter to track patient status.

---

Q: Does Masivet affect the immune system?

Official documents indicate that Masivet is contraindicated, or should not be used, in patients who have pre-existing blood disorders like neutropenia or anemia. These are potential adverse reactions, and blood cell counts must be monitored during therapy.

---

Q: Does Masivet cause changes in appetite or weight?

According to the official product information, loss of appetite (anorexia) is listed as a very common adverse reaction. Any changes in appetite or weight should be noted and reported to the patient's healthcare provider.

---

Q: What is the documented evidence regarding long-term response to Masivet?

Studies supporting the regulatory approval reported that the Masivet group achieved specific survival outcomes at both 12 and 24 months compared to the control group. This evidence was observed in patients with non-resectable mast cell tumours during clinical trials.

---

Q: What are the general expectations for patient monitoring during Masivet use?

Official prescribing information recommends monitoring several health factors throughout the treatment period. This includes testing renal function (kidney health), checking albumin levels, and regularly assessing blood cell counts and liver enzyme concentrations.

---

Q: Is Masivet used for any condition besides the primary one it treats?

Masivet is indicated only for the treatment of non-resectable Grade 2 or 3 mast cell tumours. Furthermore, this is limited to those tumours that have been confirmed to possess the mutated c-kit tyrosine kinase receptor. Any other use falls outside of the authorized regulatory indication.

---

Q: Is there a specific time of day Masivet is usually recommended to be taken?

Regulatory documentation specifies that the tablets must be administered once daily with food and should always be given in the same manner. However, official information does not designate a specific time of day (such as morning or evening) for administration.

---

Q: What should be done if I experience a skin rash while taking Masivet?

Official regulatory sources list dermal signs as a common adverse reaction. If such effects are observed, the treatment plan may need to be adjusted or temporarily discontinued to manage the adverse effects. It is important that a veterinarian be consulted promptly for guidance on the proper course of action.

---

Q: Is Masivet a prescription-only medication?

Yes, Masivet is formally classified as a prescription-only veterinary medicine. Its use and dispensing must comply with local veterinary regulations.

---

Q: Are there specific symptoms that signal an overdose of Masivet?

The official overdose information indicates that the drug's toxicity primarily targets the gastrointestinal tract, the blood-forming system, the kidney, and the liver. If signs of adverse events or overdose are suspected, the veterinarian must be contacted so they can determine if treatment should be discontinued immediately.

Storage and Stability

Masivet tablets must be stored below 25 C. To maintain the official 4-year shelf-life approved by the European Medicines Agency (EMA), the product must be kept in its original packaging and the bottle must be tightly closed for protection against humidity.

Safe Handling and Access Restrictions

Tablets must be administered whole and should not be divided, broken, or crushed. Wear protective gloves when handling the tablets and when disposing of the treated animal's vomit, urine, or faeces to prevent skin contact. If accidental contact with skin or eyes occurs, rinse immediately with plenty of water. The product must be stored securely out of reach of children and pets.

Official Disposal Rules

Unused or expired Masivet should never be disposed of via household waste or wastewater. For proper destruction that helps protect the environment, the product remnants must be returned to a veterinarian or pharmacy in accordance with local environmental regulations.